GlycoNex Inc. announced on 17 February that it has recently launched a Phase I human clinical trial in Taiwan for its new cancer drug GNX-102, following a successful Phase I clinical trial in the United States. It has completed its first patient intake with two Taiwan medical centres to accelerate the trial process.

GNX-102 is a new anti-body drug targeting a variety of solid tumors, which binds to abnormal sugar molecules on the surface of cancer cells to inhibit tumor growth. GNX-102 is currently being tested in the US in patients with colorectal cancer, non-small cell lung cancer, pancreatic cancer, epithelial uterine cancer and other indications.

In addition to clinical trials to validate the safety and efficacy of GNX-102, GlycoNex Inc. has also recently initiated the development of a strategy for GNX-102.

Increasingly, clinical studies have shown that even if cancer patients have the target molecule of the drug, their own genetic profiles, physiological functions and other "individual differences" often affect the interaction of the drug in the patient's body, which in turn affects the cancer inhibitory effect of the drug.

In recent years, the concept of "precision medicine" has been flourishing in Taiwan, with various testing technologies (e.g. next-generation genetic sequencing NGS) quickly and comprehensively analyzing patients' bodies and providing precise treatment guidelines after interpretation by clinicians.

Therefore, the company will introduce advanced technology platforms from home and abroad to conduct large-scale human tumor analysis by combining next-generation gene sequencing to fully analyze the interaction between GNX102 and cancer cells, with the aim of identifying key molecules and important pathways for GNX-102 to effectively inhibit tumors.

GNX-102 has the potential to treat a wide range of cancers, and is expected to capture the US$1.35 trillion global cancer drug market in the future. This not only confirms the novelty and uniqueness of GNX-102 for cancer treatment, but also ensures the exclusive development rights of Glycoconjugate, which will provide a boost to the future development of GNX-102 in the global market. Currently, GNX-102 has been patented in the US and Korea, and has entered the final approaval stage in key markets such as the EU, Japan, Canada and China, and is expected to receive patent approval in the near future.